Nogo-A inhibition demonstrates potential for spinal cord injury recovery

The latest study results have been published online in the renowned “The Lancet Neurology” journal. A multi-centre clinical trial (NISCI trial: Nogo-A Inhibition in acute Spinal Cord Injury Study) investigated the antibody NG 101 (anti-Nogo-A), which blocks and thus neutralizes the body’s own Nogo-A protein.

Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules | Psychedelic Invest

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical

May 14, 2024

Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity

Researchers identified how SARS-CoV-2 targets and manipulates specific lung cells, using innovative techniques to trace the virus’s impact on the cells’ gene expression, revealing insights

April 15, 2024

FTC challenges several big drugmakers over inaccurate or improper patent listings

Making good on a recent threat, the U.S. Federal Trade Commission is challenging more than 100 patents on brand-name medicines that were improperly or inaccurately

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.